Diabetes Mellitus and History of Tuberculosis Treatment as Risk Factors of Developing Multidrug-Resistant Tuberculosis at TB Polyclinic Dr. Soetomo General Hospital 2019 - 2020
Abstract
Multidrug-Resistant Tuberculosis (MDR TB) is a condition when Mycobacterium tuberculosis were resistant to Isoniazid and Rifampicin simultaneously, with or without being followed by other first-line Anti-Tuberculosis Drugs. Diabetic patients who also have TB are more susceptible to drug resistance. There is ample evidence noting that a history of previous TB treatment is one of the main factors contributing to the development of MDR TB. This study was a case-control study. The sample of this study was all patients from TB Polyclinic Dr. Soetomo Hospital who were diagnosed with pulmonary TB by pulmonologists on January 1, 2019 – December 31, 2020, who met the inclusion criteria. The data obtained were analyzed using the IBM SPSS Statistics 23 application with a binary logistic regression test.There were 178 samples of this study. MDR TB (65.8%) was the dominant resistance type in Drug-Resistant Tuberculosis (DR TB) patients. Patients with DM were 2.2 times more likely to develop MDR TB than patients without DM. Patients with histories of previous tuberculosis (TB) treatment tended to be three times more likely to develop MDR TB than new patients. Other factors such as age, sex, BMI, history of alcohol consumption, and history of smoking did not show a significant relationship with the incidence of MDR TB. Diabetes Mellitus comorbidity and history of previous Tuberculosis treatment were significant risk factors for developing MDR TB.
Keywords
Full Text:
PDFReferences
Adane, K., Ameni, G., Bekele, S., Abebe, M., & Aseffa, A. 2015. Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia. BMC public health, 15(1), 1-8.
Adiwinata, R., Rasidi, J., & Marpaung, M. 2018. Clinical Profile and Treatment Evaluation of Rifampicin-Resistant and Multidrug-Resistant Tuberculosis Patients at Dr. Kanujoso Djatiwibowo Public Hospital, Balikpapan. Jurnal Respirologi Indonesia, 38(3), 135-142.
Akaputra, R., Burhan, E., & Nawas, A. 2008. Karakteristik dan Evaluasi Perjalanan Penyakit Multidrug Resistant Tuberculosis dengan Diabetes Melitus dan Non Diabetes Melitus. Diabetes, 2, 3.
BPS. 2020, Konsumsi Alkohol Oleh Penduduk Umur ≥ 15 Tahun Dalam Satu Tahun Terakhir (Liter Per Kapita), 2018-2020. Cited June 30 2021. Available from:
https://www.bps.go.id/indicator/30/1475/1/konsumsi-alkohol-oleh-penduduk-umur-15-tahun-dalam-satu-tahun-terakhir.html
Cao, Z., Lan, Y., Chen, L., Xiang, M., Peng, Z., Zhang, J., & Zhang, H. 2019. Resistance to first-line antituberculosis drugs and prevalence of pncA mutations in clinical isolates of Mycobacterium tuberculosis from Zunyi, Guizhou Province of China. Infection and drug resistance, 12, 3093.
Chang, J. T., Dou, H. Y., Yen, C. L., Wu, Y. H., Huang, R. M., Lin, H. J., ... & Shieh, C. C. 2011. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. Journal of the Formosan Medical Association, 110(6), 372-381.
Colijn, C., Cohen, T., Ganesh, A., & Murray, M. 2011. Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PloS one, 6(3), e18327.
Eshetie, S., Gizachew, M., Dagnew, M., Kumera, G., Woldie, H., Ambaw, F., ... & Moges, F. 2017. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC infectious diseases, 17(1), 1-12.
Faustini, A. J. H. A., Hall, A. J., & Perucci, C. A. 2006. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax, 61(2), 158-163.
Fisher-Hoch, S. P., Whitney, E., McCormick, J. B., Crespo, G., Smith, B., Rahbar, M. H., ... & And The Nuevo Santander Tuberculosis Trackers. 2008. Type 2 diabetes and multidrug-resistant tuberculosis. Scandinavian journal of infectious diseases, 40(11-12), 888-893.
Gagneux, S., Burgos, M. V., DeRiemer, K., Enciso, A., Muñoz, S., Hopewell, P. C., ... & Pym, A. S. 2006. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS pathogens, 2(6), e61.
Glasauer, S., Altmann, D., Hauer, B., Brodhun, B., Haas, W., & Perumal, N. 2019. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017. PLoS One, 14(6), e0217597.
Günther, G., Van Leth, F., Alexandru, S., Altet, N., Avsar, K., Bang, D., ... & Lange, C. 2015. Multidrug-resistant tuberculosis in Europe, 2010–2011. Emerging infectious diseases, 21(3), 409.
Kemenkes RI. PETUNJUK TEKNIS PENATALAKSANAAN TUBERKULOSIS RESISTEN OBAT DI INDONESIA 2020. Cited August 19 2021. Available from: https://tbindonesia.or.id/pustaka/pedoman/tb-ro/petunjuk-teknis-penatalaksanaan-tuberkulosis-resistan-obat-di-indonesia/
Kemenkes RI. Tabel Batas Ambang indeks Massa tubuh (IMT) 2019. Cited August 26 2020. Available from: http://www.p2ptm.kemkes.go.id/infographic-p2ptm/obesitas/tabel-batas-ambang-indeks-massa-tubuh-imt
Liang, L., Wu, Q., Gao, L., Hao, Y., Liu, C., Xie, Y., ... & Han, L. 2012. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax, 67(7), 632-638.
Mekonnen, F., Tessema, B., Moges, F., Gelaw, A., Eshetie, S., & Kumera, G. 2015. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia. BMC infectious diseases, 15(1), 1-6.
Merza, M. A., Farnia, P., Tabarsi, P., Khazampour, M., Masjedi, M. R., & Velayati, A. A. 2011. Anti-tuberculosis drug resistance and associated risk factors in a tertiary level TB center in Iran: a retrospective analysis. The Journal of Infection in Developing Countries, 5(07), 511-519.
Mi, F., Jiang, G., Du, J., Li, L., Yue, W., Harries, A. D., ... & Lin, Y. 2014. Is resistance to anti-tuberculosis drugs associated with type 2 diabetes mellitus? A register review in Beijing, China. Global health action, 7(1), 24022.
More, S. W., Parande, M. A., Kamble, S. W., & Kamble, M. S. 2017. Profile of drug-resistant tuberculosis in Western Maharashtra. Journal of family medicine and primary care, 6(1), 29.
Mulu, W., Mekkonnen, D., Yimer, M., Admassu, A., & Abera, B. 2015. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. African health sciences, 15(2), 368-377.
Nawas, A. 2010. Penatalaksanaan TB MDR Dan Strategi DOTS Plus. Jurnal Tuberkulosis Indonesia, 7(10), 1-7.
Nijland, H. M., Ruslami, R., Stalenhoef, J. E., Nelwan, E. J., Alisjahbana, B., Nelwan, R. H., ... & Van Crevel, R. 2006. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clinical Infectious Diseases, 43(7), 848-854.
OECD. Demography - Working age population 2021. Cited August 27 2021. Available from: https://data.oecd.org/pop/working-age-population.htm
Pasipanodya, J. G., Srivastava, S., & Gumbo, T. 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clinical Infectious Diseases, 55(2), 169-177.
Putri, V. A., Yovi, I. Y., & Fauzia, D. 2015. Profil Pasien Tuberculosis Multidrug Resistance (TB-MDR) Di Poliklinik TB-MDR RSUD Arifin Achmad Provinsi Riau Periode April 2013-Juni 2014 (Doctoral dissertation, Riau University).
Rifat, M., Milton, A. H., Hall, J., Oldmeadow, C., Islam, M. A., Husain, A., ... & Siddiquea, B. N. 2014. Development of multidrug resistant tuberculosis in Bangladesh: a case-control study on risk factors. PloS one, 9(8), e105214.
Rumende, C. M. 2018. Risk factors for multidrug-resistant tuberculosis. Acta Medica Indonesiana, 50(1), 1.
Samuels, J. P., Sood, A., Campbell, J. R., Khan, F. A., & Johnston, J. C. 2018. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Scientific reports, 8(1), 1-13.
Schaible, U. E., & Kaufmann, S. H. E. 2007. Malnutrition and infection: complex mechanisms and global impacts. PLoS medicine, 4(5), e115.
Shariff, N. M., Shah, S. A., & Kamaludin, F. 2016. Previous treatment, sputum-smear nonconversion, and suburban living: The risk factors of multidrug-resistant tuberculosis among Malaysians. International journal of mycobacteriology, 5(1), 51-58.
Sharma, S. K., & Mohan, A. 2006. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest, 130(1), 261-272.
Sinha, P., Srivastava, G. N., Gupta, A., & Anupurba, S. 2017. Association of risk factors and drug resistance pattern in tuberculosis patients in North India. Journal of global infectious diseases, 9(4), 139.
Surkova, L., Horevich, H. L., Titov, L. P., Sahalchyk, E., Arjomandzadegan, M., Alinejad, S., & Sadrnia, M. 2012. A study on demographic characteristics of drug resistant Mycobacterium tuberculosis isolates in Belarus. International journal of mycobacteriology, 1(2), 75-81.
Tirtana, B. T., & Musrichan, M. 2011. Faktor-faktor yang mempengaruhi keberhasilan pengobatan pada pasien tuberkulosis paru dengan resistensi obat tuberkulosis di wilayah Jawa Tengah (Doctoral dissertation, Faculty of Medicine).
Wang, K., Chen, S., Wang, X., Zhong, J., Wang, X., Huai, P., ... & Ma, W. 2014. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case–control study from China. Microbial drug resistance, 20(4), 294-300.
WHO. Adolescent Health 2021. Cited August 26 2021. Available from:
https://www.who.int/health-topics/adolescent-health#tab=tab_1
WHO, 2020, Global Tuberculosis Report 2020, Cited April 28 2020. Available from:
https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf
WHO. Tuberculosis 2020. Cited April 28 2020. Available from:
https://www.who.int/health-topics/tuberculosis#tab=tab_1
Zhang, Y., & Yew, W. W. 2015. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. The International Journal of Tuberculosis and Lung Disease, 19(11), 1276-1289.
DOI: http://dx.doi.org/10.33087/jiubj.v22i1.1908
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
|
